SlideShare a Scribd company logo
unexplained infertility Prof. Aboubakr Elnashar Benha University Hospital, EGYPT E-mail: elnashar53@hotmail.com Update on management of
Definition Inability to conceive after one year with  routine (standard, basic)  investigations of infertility showing no abnormality.  (RCOG guidelines,1998; Randolph,2000)
Prevalence Depend on:  Evaluation protocol Referral pattern,  Interpretation of diagnostic  studies 10-20%  (Balen,2003) Decreasing:   (Collins & Crosignani,1992)
 
Effect of unexplained infertility  on psychosexual function Depression   or history of depression were significantly higher in women with unexplained infertility than in the control group (Meller et al, 2002) Unexplained infertility:  prolonged & mutual agony &   sexual dysfunction .  Recognition of the cause of infertility: acceptance of childlessness & return to normal sexual behavior.
CAUSES It is possible to draw long list of  putative & subtle  causes of infertility, Many  are  uncertain  Many have been  found in  couples of  normal fertility.  Few are actually treatable   (Balen,2003)   .
I.  Ovarian & endocrine factors : 1. Abnormal follicle growth 2. Lutenized unruptured follicle 3. Hypersecretion of LH. 4. Hypersecretion of prolactin in the presence of ovulation 5. Reduced growth hormone secretion/sensitivity 6. Cytologic abnormalities of in oocytes. 7. Genetic abnormalities in oocytes 8. Antibodies to zona pellucida Putative Subtle Uncertain Found in fertile couples
II.  Peritoneal factors. 1. Altered macrophage & immune activities. 2. Mild endometriosis 3. Antichlamydial antibodies III.Tubal factors 1. Abnormal peristalsis or cilial activity 2. Altered macrophage & immune activity Putative Subtle Uncertain Found in fertile couples
IV. Endometrial factors 1. Abnormal secretion of endometrial proteins 2. Abnomal integrin/adhesion molecule 3. Abnormal T cell & natural killer cell activity. 4. Secretion of embyotoxic factors 5. Abnormalities in uterine perfusion V.  Cervical factors 1. Altered cervical mucus 2. Increased cell-mediated immunity Putative Subtle Uncertain Found in fertile couples
VI.  Male factors 1. Reduction in motility, acrosome reaction, oocyte binding & zona penetration 2. Ultrastructural abnormalities of head abnormalities VII.  Embryological factors 1. Poor quality embryo 2. Reduced progression to blastocyst in vitro 3. Abnormal chromosomal complement- increased miscarriage rate Putative Subtle Uncertain Found in fertile couples
DIAGNOSIS UI is a diagnosis of exclusion To establish the diagnosis of UI the clinician should consider the following  (Moghissi et al,2000) Was the infertility evaluation  1. complete?   2.  performed  correctly?  3.interpreted  appropriately?
European Society of Human Reproduction & Embryology (ESHRE)  (2000)  Infertility testing should be classified into 3 groups  depending on correlation with pregnancy rates I.  Tests that have an   established   association with pregnancy:   Conventional semen analysis Tubal patency tests,  Tests of ovulation
II.  Tests that are   not consistently   associated with pregnancy:   Post-coital test,  Antisperm antibody tests Zona-free hamster egg penetration test III.  Tests that have   no   association with pregnancy:  Endometrial biopsy Varicocele assessment Chlamydia testing
STANDARD (BASIC,Routine) INVESTIGATIONS A.  Balen (2003),RCOG Guidelines (1998), Cooke (1999),National Guideline Clearinghouse  (2000)  : 1. Basic semen analysis. 2. HSG 3. Mid luteal serum progestrone. There is no value in measuring  thyroid or prolactin  in women with regular menstrual cycle, in the absence of galactorrhea or symptoms of thyroid disease (RCOG guidelines,1998).
B. American Society of  Reproductive Medicine (ASRM)(1992)& Randolph (2000) 1.   Basic semen analysis :  2. HSG:   document a normal endometrial cavity & tubal patency but it is less predictive of pelvic pathology.
3.  Assessment of occurrence & adequacy of ovulation:  Mid-luteal srerum progesterone:  less invasive  way to assess luteal function, controversy persists regarding the  lower limit of normal.
b. LH surge in urine:   sensitive, relatively inexpensive,  pinpoint the day of ovulation &  has reduced the uncertainty in  interpretation   of progesterone levels by better-identifying the time of peak progestrone secretion at which to obtain serum
4   .  Laparoscopy:   Indicated in presence of  an abnormal HSG or  history or symptoms suggestive of pelvic disease.  In women with normal HSG or without history suggestive of tubal disease, The probability of clinically relevant tubal disease or endometriosis is very low & laparoscopy is not justified or cost effective (Fatum et al, 2002).
Laparoscopy may  reveal  minimal or mild  endometriosis  or  peritubal adhesions . In these cases either surgery or medical treatment has not been proven to improve fecunditity.  With the current success rates of ART& the relatively low contribution of diagnostic laparoscopy to the decision making of treating patients with normal HSG, laparoscopy should be omitted in couples with unexplained infertility.  These patients should be treated as UI  (by 3 cycles of combined gonadotropins & IUI & if unsuccessful ART)
Treatment What is the treatment?   Once the well-known & obvious causes of infertility have been excluded , the treatment of couples with unexplained infertility is the same  (Balen,2003)  .  In UI:  the disease is not defined, so treatment is empirical ( Soules , 2000 )
What aim of the treatment?:   to increase the monthly pregnancy rate above the natural rate of  1.5-3% How?:   improve gamete quality increase gamete number facilitate gamete interaction.
When?:   depend on  1.duration of infertility 2. woman , s age &  3.the previous pregnancy history
Combined pregnancy rates per cycle  (Guzik et al, 1998) No treatment  1.3%  IUI  3.8% CC  5.6% CC with IUI  8.3% HMG  7.7% HMG with IUI  17.1% IVF/ICSI  20.7% Alternative therapies
I.Expectant therapy The spontaneous monthly fecundity rate: 1.3% After 3yr:  60%  will conceive spontaneously  (Godon &  Sperof,2002) After 5 yr:  80%   (Randolph,2000) Unfortunately, it is not possible to  predict   which couples will conceive spontaneously or in what time frame.
Expectant therapy for 6-12 mo.:   < 35yr. or <3 yr. of  infertility,  Aggressive therapy:   > 35yr. or  >3 yr. of infertility  (Soules,2000).
A nonhomogenous hyperechogenic sonographic endometrial echo pattern   predicts lower fertility potential  in women who are not receiving follicle maturing drugs in unexplained infertility  (Check et al, 2003)
II. IUI: The spontaneous monthly fecundity rate for IUI alone:  3.8 %   (Guzik et al,1988)  to  7.4%   (Goverde et al,2000)
 
III.   Clomiphene citrate: CC enhances fertility by: 1.Correcting subtle defect in ovarian function-either follicular development or luteal phase defect 2. Increasing the number of follicles that develop & consequently oocyte that are released  (Balen,2003).
Pregnancy rate for cycle: 5.6% Although small increase in  fecundity,   the low cost &  ease of administration,  CC is a sensible first choice treatment  (Cochrane,2001) .
IV. Gonadotropins: Per cycle pregnancy rate  of 7.7% for gonadotrpin alone  (Guzick et al,1998). Oral ovulation induction agents had significantly reduced odds of pregnancy per women compared to injectable ovulation induction agents (Athaullah et al, 2002, Chochrane review)
V. Stimulation & IUI: CC with IUI:   pregnancy rate of  6.7%  per cycle  (Guzick et al,1998).   It is cost effective TT.
Gonadotropins with IUI:   18%  per cycle pregnancy rate  (Guzick et al,1998).   The cycle fecundity in the first  3 trials  of COH & IUI was higher than in cycles 4-6 COH & IUI should be limited to 3 trials (Aboulghar et al,2001) .
VI.  IVF/ICSI:   Rationales:   1.To increase the  number & quality  of oocytes available for fertilization, 2. To facilitate the sperm-oocyte  interaction & enhance fertilization,  3. To document the occurrence of  fertilization , & to evaluate embryo quality  (Randolph,2000) . Cycle fecundity rate:  25.7%  (ESHRE).
1.   IVF Vs Expectant management: There was no significant difference in clinical pregnancy rate between  IVF & expectant management   (Pandian et al,2003, Cochrane review).
2. IVF Vs IUI There was no evidence of difference in live birth rates between  IVF & IUI   either without or with ovulation stimulation.  The effectiveness of IVF in unexplained infertility remains unproven  (Pandian et al,2003, Cochrane review).   The initial treatment of UI should be IUI as opposed to IVF  (Homburg,2003)
3.IVF Vs ICSI: Complete fertilization failure was higher in conventional  IVF (34.3%) than ICSI (10.3%)  cycles in unexplained infertility  (Jaroudi et al,2003).   ICSI should be  the first option  for in vitro fertilization in unexplained infertility  (Sertac et al,2000).  ICSI should be the first line therapy for women over 35 yrs  (Balen,2003)
 
VII.  Alternative therapies: 1 . Bromcriptine  is not effective  (Cochrane,2001) . 2.  Danazol  is not effective  (Cochrane,2001) . 3.  Fallopian tube sperm perfusion:  had insufficient evidence to support use in pooled analysis  (Cochrane,2001)
4.  Oil soluble HSG:   is associated with  increased  cycle fecundity when compared with water soluble  (Cochrane,2001).  There was a statistically  significantly higher  pregnancy rates in couples with UI randomized to a single tubal flush with lipiodol compared with no treatment  (Nugnet et al,2002)
5.  Letrozole:   an oral, reversible, no-steroidal aromatase inhibitor.   Dose:   2.5 mg/d from day 3-7 Mechanism of action:   1. Release of the estrogen negative feedback, increase GnTR, stimulate ovarian follicle development 2. Increase sensitivity of follicles to FSH.
Advantages of letrozole over CC: Because of the short half life (45h) & absence of ER depletion No effect on the endometrial thickness or cervical mucous
Letrozole is effective for increasing follicle recruitment in UI  (Mitwally & Casper,2000) Letrozole  can replace CC in patients with UI undergoing ovulation induction & IUI  (Sammour,2001). Letrozole improved response to FSH evidenced by lower FSH dose & higher number of mature follicles in women with UI  (Mitwally & Casper, 2003)
PROGRESSIVE TREATMENT REGIMEN   (Soules,2000).  Treatment should follow an orderly progression of intensity & expense The pace & intensity of treatment  depend on  couple,s desires, anxiety & cost. Some wishing to proceed swiftly to ART & others wanting to avoid ART for as long as possible
.   D oxycyclin   for both partners  (effective for most cases of pyospermia, cervicitis, &/or endometritis) 1.  IUI  3 cycles  (simple & would treat an undiagnosed cervical or male factor) 2.  Clomifene citrate + IUI  for 3 cycles. 3.  Gonadotrophins + IUI  for 2 cycles. 4.   ICSI 75% of couples with UI will conceive after this treatment.
Effect of unexplained infertility on obstetric outcome: Women with unexplained infertility are at higher risk of  obstetric complications   which persist even after adjusting for age, parity, & fertility treatment (Pandian et al, 2001) . The reasons  are unclear.
They had higher incidence of  pre-eclampsia,  abrutio placentae,  preterm labour,  emergency cesarean section, & induction of labour  in comparison with general population.
Conclusions 1.  Incidence of UI is decreasing 2. Many causes of UI are uncertain & few of which are treatable 3. Tests that have an established association with pregnancy are semen analysis, tubal patency tests & tests of ovulation
4. Once the well-known & obvious causes of infertility has been excluded, the treatment of UI is the same 5. Treatment of UI should follow an orderly progression of intensity & expense. It includes: expectant, CC, GnTR, IUI, COH with IUI, ICSI & other alternative therapies.
Thank you Prof.Aboubakr Elnashar Benha University Hospital, EGYPT E-mail: elnashar53@hotmail.com www.obgyn.net

More Related Content

PPTX
Difficult Cases in IUI
PPTX
Thin Endometrium & Infertility
PPT
Intrauterine Insemination UPDATE 2018
PDF
#Individualization of #cos to #optimize #success
PPT
NICE Guidelines 2013, in relation to IUI & IVF Dr. Jyoti Agarwal,Dr. Sharda J...
PPTX
Individualized ovarian stimulation protocols in IVF (1).pptx
PPTX
Fertility Preserving Hysteroscopic Surgery
PPTX
Thin Endometrium & Infertility (Part – I) , Dr. Sharda Jain , Life Care Centre
Difficult Cases in IUI
Thin Endometrium & Infertility
Intrauterine Insemination UPDATE 2018
#Individualization of #cos to #optimize #success
NICE Guidelines 2013, in relation to IUI & IVF Dr. Jyoti Agarwal,Dr. Sharda J...
Individualized ovarian stimulation protocols in IVF (1).pptx
Fertility Preserving Hysteroscopic Surgery
Thin Endometrium & Infertility (Part – I) , Dr. Sharda Jain , Life Care Centre

What's hot (20)

PDF
Thin Endometrium
PDF
Role of LH in Controlled Ovarian Stimulation
PPTX
PROTOCOLS Intra Uterine Insemination (sharing personal experience)
PPTX
UNEXPLAINED INFERTILITY & INTRAUTERINE INSEMINATION Dr. Sharda jain Lifecare...
PPTX
Investigations & Evaluation of Male partner after 2 IUI failure
PDF
Current evidence for management of Refractory Endometrium
PDF
Monitoring ART cycle Aboubakr Elnashar
PPTX
MANAGEMENT OF POOR RESPONDERS IN IVF BY DR SHASHWAT JANI
PDF
Luteal phase support in IUI and ART | Dr. Laxmi Shrikhande | ShrikhandeIVF
PDF
Recent advances in stimulation protocols
PPTX
Iui - newer concepts
PPSX
CURRENT EVIDENCE ON MEDICAL ADD-ONS IN IVF
PDF
Recurrent implantation failure: British fertility society Guidelines2020
PPTX
Diagnosis and Management of Poor Ovarian Reserve : Evidence & Practice
PPTX
Sperm retrieval techniques - nuts and bolts
PDF
Use of LH in IVF and IUI
PPTX
Myoma and Infertility: What next?
PPT
15. Unexplained infertility (1).ppt
PDF
Emerging treatment of endometriosis
PPTX
Critical Analysis of ESHRE Guidelines on Unexplained Infertility
Thin Endometrium
Role of LH in Controlled Ovarian Stimulation
PROTOCOLS Intra Uterine Insemination (sharing personal experience)
UNEXPLAINED INFERTILITY & INTRAUTERINE INSEMINATION Dr. Sharda jain Lifecare...
Investigations & Evaluation of Male partner after 2 IUI failure
Current evidence for management of Refractory Endometrium
Monitoring ART cycle Aboubakr Elnashar
MANAGEMENT OF POOR RESPONDERS IN IVF BY DR SHASHWAT JANI
Luteal phase support in IUI and ART | Dr. Laxmi Shrikhande | ShrikhandeIVF
Recent advances in stimulation protocols
Iui - newer concepts
CURRENT EVIDENCE ON MEDICAL ADD-ONS IN IVF
Recurrent implantation failure: British fertility society Guidelines2020
Diagnosis and Management of Poor Ovarian Reserve : Evidence & Practice
Sperm retrieval techniques - nuts and bolts
Use of LH in IVF and IUI
Myoma and Infertility: What next?
15. Unexplained infertility (1).ppt
Emerging treatment of endometriosis
Critical Analysis of ESHRE Guidelines on Unexplained Infertility
Ad

Viewers also liked (6)

PDF
INTRAUTERINE INSEMINATION Protocol
PDF
ART: Management of associated conditions
PDF
PREMATURE OVARIAN INSUFFICIENCY ESHRE Guidelines, 2015
PDF
Gonadotrpin ovarian stimulation: Aboubakr elnashar
PDF
Infertility treatment related to PCOS
PDF
Treatment of poor responders: Review of Systematic reviews 2016
INTRAUTERINE INSEMINATION Protocol
ART: Management of associated conditions
PREMATURE OVARIAN INSUFFICIENCY ESHRE Guidelines, 2015
Gonadotrpin ovarian stimulation: Aboubakr elnashar
Infertility treatment related to PCOS
Treatment of poor responders: Review of Systematic reviews 2016
Ad

Similar to Unexplained Infertility (20)

PPTX
Unexplained Infertility - By Dr Dhorepatil Bharati
PPTX
Unexplained Infertility - By Dhorepatil Bharati
PPT
Intrauterine insemination forun explained infertility Infertilità inspiegata ...
PPTX
Optimizing iui results
PPT
Intra uterine insemination for unexplained infertility
PDF
Infertility-unexplained
PDF
Unexplained infertility
PPTX
Unexplained infertility astrakhan webinar copy
PPT
Investigation of infertility modified
PPTX
Optimizing IUI Outcome
PDF
Threatened and unexplained repeated miscarriages
PPTX
Role of IUI in the era of IVF
PPTX
Recurrent Implantation Failure
PPT
Infertility.(By Craig)
PPTX
Sms gynae letrozole treatment protocol o
PPTX
Recurrent pregnancy loss
PPTX
Patient Selection and Workup for Intrauterine Insemination (IUI)
PDF
Evidence linked treatment for endometriosis-associated infertility
PDF
Recurrent miscarriage RCOG, 2011 Up to date, 2013
PPTX
Recurrent pregnancy loss Presentation by Dr.Laxmi Shrikhande
Unexplained Infertility - By Dr Dhorepatil Bharati
Unexplained Infertility - By Dhorepatil Bharati
Intrauterine insemination forun explained infertility Infertilità inspiegata ...
Optimizing iui results
Intra uterine insemination for unexplained infertility
Infertility-unexplained
Unexplained infertility
Unexplained infertility astrakhan webinar copy
Investigation of infertility modified
Optimizing IUI Outcome
Threatened and unexplained repeated miscarriages
Role of IUI in the era of IVF
Recurrent Implantation Failure
Infertility.(By Craig)
Sms gynae letrozole treatment protocol o
Recurrent pregnancy loss
Patient Selection and Workup for Intrauterine Insemination (IUI)
Evidence linked treatment for endometriosis-associated infertility
Recurrent miscarriage RCOG, 2011 Up to date, 2013
Recurrent pregnancy loss Presentation by Dr.Laxmi Shrikhande

More from guest7f0a3a (20)

PPT
Recent Trends In Art (2)
PPT
Ivm Of Oocytes Study (1)
PDF
PPT
Ivm Of Oocytes Study
PPT
Ivm Implementation Mnzava
PPT
Ivm Medi Cult 03 07 V2
PPT
Jensen Sterilitaet
PPT
Ov Function Shoham
PPT
Jensen Sterilitaet (1)
PPT
New Developments In Reproductive Medicine
PPT
Ov Function Shoham (1)
PPT
Wheeler
PPT
Recent Trends In Art
PPT
Presentation Marcelle
PPT
Recent Trends In Art (1)
PPT
Ultrasound
PPT
Ultrasound (1)
PPT
Unexplained Infertility
PPT
Unexplained Infertility (1)
PPT
Presentation Marcelle
Recent Trends In Art (2)
Ivm Of Oocytes Study (1)
Ivm Of Oocytes Study
Ivm Implementation Mnzava
Ivm Medi Cult 03 07 V2
Jensen Sterilitaet
Ov Function Shoham
Jensen Sterilitaet (1)
New Developments In Reproductive Medicine
Ov Function Shoham (1)
Wheeler
Recent Trends In Art
Presentation Marcelle
Recent Trends In Art (1)
Ultrasound
Ultrasound (1)
Unexplained Infertility
Unexplained Infertility (1)
Presentation Marcelle

Recently uploaded (20)

PPT
Rheumatology Member of Royal College of Physicians.ppt
PPTX
Cardiovascular - antihypertensive medical backgrounds
PPTX
surgery guide for USMLE step 2-part 1.pptx
PPT
Obstructive sleep apnea in orthodontics treatment
PDF
Copy of OB - Exam #2 Study Guide. pdf
PPTX
Stimulation Protocols for IUI | Dr. Laxmi Shrikhande
PDF
Oral Aspect of Metabolic Disease_20250717_192438_0000.pdf
PPTX
MANAGEMENT SNAKE BITE IN THE TROPICALS.pptx
PPTX
ONCOLOGY Principles of Radiotherapy.pptx
PPTX
the psycho-oncology for psychiatrists pptx
PPTX
CHEM421 - Biochemistry (Chapter 1 - Introduction)
PPT
MENTAL HEALTH - NOTES.ppt for nursing students
PPTX
PRESENTACION DE TRAUMA CRANEAL, CAUSAS, CONSEC, ETC.
PPTX
Post Op complications in general surgery
PPTX
Reading between the Rings: Imaging in Brain Infections
PPTX
NRPchitwan6ab2802f9.pptxnepalindiaindiaindiapakistan
PPTX
Neuropathic pain.ppt treatment managment
PPTX
Human Reproduction: Anatomy, Physiology & Clinical Insights.pptx
PPTX
obstructive neonatal jaundice.pptx yes it is
PPTX
y4d nutrition and diet in pregnancy and postpartum
Rheumatology Member of Royal College of Physicians.ppt
Cardiovascular - antihypertensive medical backgrounds
surgery guide for USMLE step 2-part 1.pptx
Obstructive sleep apnea in orthodontics treatment
Copy of OB - Exam #2 Study Guide. pdf
Stimulation Protocols for IUI | Dr. Laxmi Shrikhande
Oral Aspect of Metabolic Disease_20250717_192438_0000.pdf
MANAGEMENT SNAKE BITE IN THE TROPICALS.pptx
ONCOLOGY Principles of Radiotherapy.pptx
the psycho-oncology for psychiatrists pptx
CHEM421 - Biochemistry (Chapter 1 - Introduction)
MENTAL HEALTH - NOTES.ppt for nursing students
PRESENTACION DE TRAUMA CRANEAL, CAUSAS, CONSEC, ETC.
Post Op complications in general surgery
Reading between the Rings: Imaging in Brain Infections
NRPchitwan6ab2802f9.pptxnepalindiaindiaindiapakistan
Neuropathic pain.ppt treatment managment
Human Reproduction: Anatomy, Physiology & Clinical Insights.pptx
obstructive neonatal jaundice.pptx yes it is
y4d nutrition and diet in pregnancy and postpartum

Unexplained Infertility

  • 1. unexplained infertility Prof. Aboubakr Elnashar Benha University Hospital, EGYPT E-mail: elnashar53@hotmail.com Update on management of
  • 2. Definition Inability to conceive after one year with routine (standard, basic) investigations of infertility showing no abnormality. (RCOG guidelines,1998; Randolph,2000)
  • 3. Prevalence Depend on: Evaluation protocol Referral pattern, Interpretation of diagnostic studies 10-20% (Balen,2003) Decreasing: (Collins & Crosignani,1992)
  • 4.  
  • 5. Effect of unexplained infertility on psychosexual function Depression or history of depression were significantly higher in women with unexplained infertility than in the control group (Meller et al, 2002) Unexplained infertility: prolonged & mutual agony & sexual dysfunction . Recognition of the cause of infertility: acceptance of childlessness & return to normal sexual behavior.
  • 6. CAUSES It is possible to draw long list of putative & subtle causes of infertility, Many are uncertain Many have been found in couples of normal fertility. Few are actually treatable (Balen,2003) .
  • 7. I. Ovarian & endocrine factors : 1. Abnormal follicle growth 2. Lutenized unruptured follicle 3. Hypersecretion of LH. 4. Hypersecretion of prolactin in the presence of ovulation 5. Reduced growth hormone secretion/sensitivity 6. Cytologic abnormalities of in oocytes. 7. Genetic abnormalities in oocytes 8. Antibodies to zona pellucida Putative Subtle Uncertain Found in fertile couples
  • 8. II. Peritoneal factors. 1. Altered macrophage & immune activities. 2. Mild endometriosis 3. Antichlamydial antibodies III.Tubal factors 1. Abnormal peristalsis or cilial activity 2. Altered macrophage & immune activity Putative Subtle Uncertain Found in fertile couples
  • 9. IV. Endometrial factors 1. Abnormal secretion of endometrial proteins 2. Abnomal integrin/adhesion molecule 3. Abnormal T cell & natural killer cell activity. 4. Secretion of embyotoxic factors 5. Abnormalities in uterine perfusion V. Cervical factors 1. Altered cervical mucus 2. Increased cell-mediated immunity Putative Subtle Uncertain Found in fertile couples
  • 10. VI. Male factors 1. Reduction in motility, acrosome reaction, oocyte binding & zona penetration 2. Ultrastructural abnormalities of head abnormalities VII. Embryological factors 1. Poor quality embryo 2. Reduced progression to blastocyst in vitro 3. Abnormal chromosomal complement- increased miscarriage rate Putative Subtle Uncertain Found in fertile couples
  • 11. DIAGNOSIS UI is a diagnosis of exclusion To establish the diagnosis of UI the clinician should consider the following (Moghissi et al,2000) Was the infertility evaluation 1. complete? 2. performed correctly? 3.interpreted appropriately?
  • 12. European Society of Human Reproduction & Embryology (ESHRE) (2000) Infertility testing should be classified into 3 groups depending on correlation with pregnancy rates I. Tests that have an established association with pregnancy: Conventional semen analysis Tubal patency tests, Tests of ovulation
  • 13. II. Tests that are not consistently associated with pregnancy: Post-coital test, Antisperm antibody tests Zona-free hamster egg penetration test III. Tests that have no association with pregnancy: Endometrial biopsy Varicocele assessment Chlamydia testing
  • 14. STANDARD (BASIC,Routine) INVESTIGATIONS A. Balen (2003),RCOG Guidelines (1998), Cooke (1999),National Guideline Clearinghouse (2000) : 1. Basic semen analysis. 2. HSG 3. Mid luteal serum progestrone. There is no value in measuring thyroid or prolactin in women with regular menstrual cycle, in the absence of galactorrhea or symptoms of thyroid disease (RCOG guidelines,1998).
  • 15. B. American Society of Reproductive Medicine (ASRM)(1992)& Randolph (2000) 1. Basic semen analysis : 2. HSG: document a normal endometrial cavity & tubal patency but it is less predictive of pelvic pathology.
  • 16. 3. Assessment of occurrence & adequacy of ovulation: Mid-luteal srerum progesterone: less invasive way to assess luteal function, controversy persists regarding the lower limit of normal.
  • 17. b. LH surge in urine: sensitive, relatively inexpensive, pinpoint the day of ovulation & has reduced the uncertainty in interpretation of progesterone levels by better-identifying the time of peak progestrone secretion at which to obtain serum
  • 18. 4 . Laparoscopy: Indicated in presence of an abnormal HSG or history or symptoms suggestive of pelvic disease. In women with normal HSG or without history suggestive of tubal disease, The probability of clinically relevant tubal disease or endometriosis is very low & laparoscopy is not justified or cost effective (Fatum et al, 2002).
  • 19. Laparoscopy may reveal minimal or mild endometriosis or peritubal adhesions . In these cases either surgery or medical treatment has not been proven to improve fecunditity. With the current success rates of ART& the relatively low contribution of diagnostic laparoscopy to the decision making of treating patients with normal HSG, laparoscopy should be omitted in couples with unexplained infertility. These patients should be treated as UI (by 3 cycles of combined gonadotropins & IUI & if unsuccessful ART)
  • 20. Treatment What is the treatment? Once the well-known & obvious causes of infertility have been excluded , the treatment of couples with unexplained infertility is the same (Balen,2003) . In UI: the disease is not defined, so treatment is empirical ( Soules , 2000 )
  • 21. What aim of the treatment?: to increase the monthly pregnancy rate above the natural rate of 1.5-3% How?: improve gamete quality increase gamete number facilitate gamete interaction.
  • 22. When?: depend on 1.duration of infertility 2. woman , s age & 3.the previous pregnancy history
  • 23. Combined pregnancy rates per cycle (Guzik et al, 1998) No treatment 1.3% IUI 3.8% CC 5.6% CC with IUI 8.3% HMG 7.7% HMG with IUI 17.1% IVF/ICSI 20.7% Alternative therapies
  • 24. I.Expectant therapy The spontaneous monthly fecundity rate: 1.3% After 3yr: 60% will conceive spontaneously (Godon & Sperof,2002) After 5 yr: 80% (Randolph,2000) Unfortunately, it is not possible to predict which couples will conceive spontaneously or in what time frame.
  • 25. Expectant therapy for 6-12 mo.: < 35yr. or <3 yr. of infertility, Aggressive therapy: > 35yr. or >3 yr. of infertility (Soules,2000).
  • 26. A nonhomogenous hyperechogenic sonographic endometrial echo pattern predicts lower fertility potential in women who are not receiving follicle maturing drugs in unexplained infertility (Check et al, 2003)
  • 27. II. IUI: The spontaneous monthly fecundity rate for IUI alone: 3.8 % (Guzik et al,1988) to 7.4% (Goverde et al,2000)
  • 28.  
  • 29. III. Clomiphene citrate: CC enhances fertility by: 1.Correcting subtle defect in ovarian function-either follicular development or luteal phase defect 2. Increasing the number of follicles that develop & consequently oocyte that are released (Balen,2003).
  • 30. Pregnancy rate for cycle: 5.6% Although small increase in fecundity, the low cost & ease of administration, CC is a sensible first choice treatment (Cochrane,2001) .
  • 31. IV. Gonadotropins: Per cycle pregnancy rate of 7.7% for gonadotrpin alone (Guzick et al,1998). Oral ovulation induction agents had significantly reduced odds of pregnancy per women compared to injectable ovulation induction agents (Athaullah et al, 2002, Chochrane review)
  • 32. V. Stimulation & IUI: CC with IUI: pregnancy rate of 6.7% per cycle (Guzick et al,1998). It is cost effective TT.
  • 33. Gonadotropins with IUI: 18% per cycle pregnancy rate (Guzick et al,1998). The cycle fecundity in the first 3 trials of COH & IUI was higher than in cycles 4-6 COH & IUI should be limited to 3 trials (Aboulghar et al,2001) .
  • 34. VI. IVF/ICSI: Rationales: 1.To increase the number & quality of oocytes available for fertilization, 2. To facilitate the sperm-oocyte interaction & enhance fertilization, 3. To document the occurrence of fertilization , & to evaluate embryo quality (Randolph,2000) . Cycle fecundity rate: 25.7% (ESHRE).
  • 35. 1. IVF Vs Expectant management: There was no significant difference in clinical pregnancy rate between IVF & expectant management (Pandian et al,2003, Cochrane review).
  • 36. 2. IVF Vs IUI There was no evidence of difference in live birth rates between IVF & IUI either without or with ovulation stimulation. The effectiveness of IVF in unexplained infertility remains unproven (Pandian et al,2003, Cochrane review). The initial treatment of UI should be IUI as opposed to IVF (Homburg,2003)
  • 37. 3.IVF Vs ICSI: Complete fertilization failure was higher in conventional IVF (34.3%) than ICSI (10.3%) cycles in unexplained infertility (Jaroudi et al,2003). ICSI should be the first option for in vitro fertilization in unexplained infertility (Sertac et al,2000). ICSI should be the first line therapy for women over 35 yrs (Balen,2003)
  • 38.  
  • 39. VII. Alternative therapies: 1 . Bromcriptine is not effective (Cochrane,2001) . 2. Danazol is not effective (Cochrane,2001) . 3. Fallopian tube sperm perfusion: had insufficient evidence to support use in pooled analysis (Cochrane,2001)
  • 40. 4. Oil soluble HSG: is associated with increased cycle fecundity when compared with water soluble (Cochrane,2001). There was a statistically significantly higher pregnancy rates in couples with UI randomized to a single tubal flush with lipiodol compared with no treatment (Nugnet et al,2002)
  • 41. 5. Letrozole: an oral, reversible, no-steroidal aromatase inhibitor. Dose: 2.5 mg/d from day 3-7 Mechanism of action: 1. Release of the estrogen negative feedback, increase GnTR, stimulate ovarian follicle development 2. Increase sensitivity of follicles to FSH.
  • 42. Advantages of letrozole over CC: Because of the short half life (45h) & absence of ER depletion No effect on the endometrial thickness or cervical mucous
  • 43. Letrozole is effective for increasing follicle recruitment in UI (Mitwally & Casper,2000) Letrozole can replace CC in patients with UI undergoing ovulation induction & IUI (Sammour,2001). Letrozole improved response to FSH evidenced by lower FSH dose & higher number of mature follicles in women with UI (Mitwally & Casper, 2003)
  • 44. PROGRESSIVE TREATMENT REGIMEN (Soules,2000). Treatment should follow an orderly progression of intensity & expense The pace & intensity of treatment depend on couple,s desires, anxiety & cost. Some wishing to proceed swiftly to ART & others wanting to avoid ART for as long as possible
  • 45. . D oxycyclin for both partners (effective for most cases of pyospermia, cervicitis, &/or endometritis) 1. IUI 3 cycles (simple & would treat an undiagnosed cervical or male factor) 2. Clomifene citrate + IUI for 3 cycles. 3. Gonadotrophins + IUI for 2 cycles. 4. ICSI 75% of couples with UI will conceive after this treatment.
  • 46. Effect of unexplained infertility on obstetric outcome: Women with unexplained infertility are at higher risk of obstetric complications which persist even after adjusting for age, parity, & fertility treatment (Pandian et al, 2001) . The reasons are unclear.
  • 47. They had higher incidence of pre-eclampsia, abrutio placentae, preterm labour, emergency cesarean section, & induction of labour in comparison with general population.
  • 48. Conclusions 1. Incidence of UI is decreasing 2. Many causes of UI are uncertain & few of which are treatable 3. Tests that have an established association with pregnancy are semen analysis, tubal patency tests & tests of ovulation
  • 49. 4. Once the well-known & obvious causes of infertility has been excluded, the treatment of UI is the same 5. Treatment of UI should follow an orderly progression of intensity & expense. It includes: expectant, CC, GnTR, IUI, COH with IUI, ICSI & other alternative therapies.
  • 50. Thank you Prof.Aboubakr Elnashar Benha University Hospital, EGYPT E-mail: elnashar53@hotmail.com www.obgyn.net